REFERENCES 1.Magkos F, Fraterrigo G, Yoshino J, Luecking C, Kirbach K, Kelly SC, et al
Overall, nearly one in five (18%) adults now say they have ever used GLP-1 agonist drugs either to lose weight or treat a chronic condition, including 12% who say they are currently using them (an increase of 6 percentage points from May 2024)
A regioselective IL-2 expression decrease was also confirmed when Epitalon was administered intranasally [90]
They work by: Reducing Appetite: Slowing down stomach emptying, making you feel fuller longer Controlling Cravings: Targeting brain receptors that regulate hunger and reward responses Stabilizing Blood Sugar: Preventing spikes and crashes that trigger overeating Enhancing Fat Loss: Supporting metabolic function and energy balance This powerful approach helps patients not only lose weight safely but also experience better blood sugar control, reduced inflammation, and improved overall health